These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26769227)

  • 1. Chronic myeloid leukemia: First-line drug of choice.
    Jabbour E
    Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting the best frontline treatment in chronic myeloid leukemia.
    Yilmaz M; Abaza Y; Jabbour E
    Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia: Second-line drugs of choice.
    Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
    Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
    Tinsley SM
    J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
    Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
    Agrawal M; Garg RJ; Kantarjian H; Cortes J
    Curr Oncol Rep; 2010 Sep; 12(5):302-13. PubMed ID: 20640942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
    Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
    Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era.
    Russo D; Malagola M; Skert C; Filì C; Bergonzi C; Cancelli V; Cattina F
    Curr Cancer Drug Targets; 2013 Sep; 13(7):755-67. PubMed ID: 23941515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The choice of first-line chronic myelogenous leukemia treatment.
    Fava C; Rege-Cambrin G; Saglio G
    Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.
    Shami PJ
    J Natl Compr Canc Netw; 2012 Jan; 10(1):112-8; quiz 119. PubMed ID: 22223871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [State-of-the-art management of CML in 2015 and future prospects].
    Kimura S
    Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
    Heaney ML
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):502-8. PubMed ID: 25356574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.